USFDA gives VAI classification to Jubilant HollisterStier Spokane facility

Regulatory & Legal View source PDF Explain this filing

JUBLPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.0%Reaction day

₹1025.10

prior close

₹1040.00

announcement price

After-mkt

timing

Nifty Smallcap 250market-2.4%+0.5% vs market

Pharmaceuticals peers, median of 172sector-1.8%-0.1% vs sector

On the reaction day the stock moved 0.5 pts more than Nifty Smallcap 250 and 0.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.1

10m

-1.4

15m

-1.5

30m

-1.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.0-2.4+0.5-1.8-0.1

Next day

-2.2-2.6+0.4-2.1-0.1

-1.0-1.8+0.8-1.2+0.2

+4.7-0.3+5.0-0.4+5.1

+2.4-0.3+2.8+0.2+2.2

+4.1-0.4+4.5-0.1+4.2

+3.8-1.0+4.8-0.2+4.0

15d

-4.9-2.3-2.6-3.0-1.9

-8.9-3.9-5.0-5.6-3.3

—————

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The USFDA has classified Jubilant HollisterStier LLC's contract manufacturing facility in Spokane, Washington as Voluntary Action Indicated (VAI) after concluding its review of the Establishment Inspection Report. The inspection took place from June 8 to June 17, 2026. VAI is the most favourable USFDA classification, meaning no mandatory corrective action is required. HollisterStier is a subsidiary within Jubilant Pharmova.

Likely market impact

Positive outcome - facility clears USFDA review with best classification, no regulatory action needed, supports ongoing CMO business and client confidence.